Pregled po CROSBI profilu: IVAN KREČAK (CROSBI Profil: 40410)
Pronađeno 74 radova
-
1.Higher JAK2 V617F mutant allele burden in patients with chronic myeloproliferative neoplasms is associated with a higher prevalence of chronic kidney disease and unfavorable dynamics of kidney function over time // Annals of Hematology (2023) doi:10.1007/s00277-023-05305-3 (međunarodna recenzija, online first)
-
2.Clinical presentation, treatment patterns, and outcomes of pulmonary embolism in patients with chronic myeloproliferative neoplasms // Thrombosis Research (2023) doi:10.1016/j.thromres.2023.03.004 (međunarodna recenzija, online first)
-
3.High plateletcrit may be associated with thrombotic risk in polycythemia vera // International Journal of Laboratory Hematology (2023) doi:10.1111/ijlh.14073 (međunarodna recenzija, online first)
-
4.Pulmonary embolism, is it healthy to be volume expanded? // European Journal of Internal Medicine (2023) doi:10.1016/j.ejim.2023.05.010 (međunarodna recenzija, online first)
-
5.Specific symptom burden in patients with chronic myeloproliferative neoplasms and chronic kidney disease // Annals of Hematology (2023) doi:10.1007/s00277-023-05296-1 (međunarodna recenzija, online first)
-
6.Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms // Biomedicines, 11 (2023), 5; 1301, 16 doi:10.3390/biomedicines11051301 (međunarodna recenzija, članak, znanstveni)
-
7.Chronic kidney disease and thrombotic risk in patients with chronic myeloproliferative neoplasms // Journal of Thrombosis and Thrombolysis, 55 (2023), 4; 760-761 doi:10.1007/s11239-023-02779-w (međunarodna recenzija, članak, znanstveni)
-
8.Hematocrit to hemoglobin ratio (HHR) may improve prognostication in patients with pulmonary embolism // Scandinavian Journal of Clinical and Laboratory Investigation, 83 (2023), 3; 200-203 doi:10.1080/00365513.2023.2191334 (međunarodna recenzija, članak, znanstveni)
-
9.Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis // Biochemia Medica, 33 (2023), 2; 020901, 8 doi:10.11613/bm.2023.020901 (međunarodna recenzija, članak, znanstveni)
-
10.Palpable spleen size is differently prognostic in primary and secondary myelofibrosis // Leukemia & lymphoma, 64 (2023), 4; 893-896 doi:10.1080/10428194.2023.2179360 (međunarodna recenzija, pismo, znanstveni)
-
11.Can we use platelet-to-lymphocyte ratio (PLR) to differentiate JAK2-unmutated erythrocytosis from polycythemia vera? // European journal of internal medicine, 108 (2023), 120-121 doi:10.1016/j.ejim.2022.09.023 (međunarodna recenzija, pismo, znanstveni)
-
12.Understanding and modifying thrombotic risk in patients with myeloproliferative neoplasms // Journal of Cardiology, 81 (2022), 6; 586-586 doi:10.1016/j.jjcc.2022.12.009 (međunarodna recenzija, pismo uredniku, znanstveni)
-
13.Higher estimated plasma volume status may be associated with an inferior survival in patients with pulmonary embolism // International journal of laboratory hematology, 45 (2022), 2; e32-e35 doi:10.1111/ijlh.13982 (međunarodna recenzija, pismo uredniku, znanstveni)
-
14.Chronic Kidney Disease has a Higher Prevalence in Polycythemia Vera than in Secondary Polycythemia, a Matched Case–Control Analysis // Indian Journal of Hematology and Blood Transfusion (2022) doi:10.1007/s12288-022-01624-z (međunarodna recenzija, online first)
-
15.P-206 Association between primary tumor site of colorectal cancer and RAS/BRAF mutational status with venous thromboembolism: A retrospective- prospective cohort study from 3 Croatian oncology centers // Abstract Book of the ESMO 24th World Congress on Gastrointestinal Cancer 2022
Barcelona, Španjolska: Elsevier BV, 2022. str. S322-S323 doi:10.1016/j.annonc.2022.04.296 (poster, međunarodna recenzija, sažetak, stručni) -
16.Sistemska mastocitoza u Republici Hrvatskoj // Liječnički vjesnik, 144 (2022), 9-10; 306-313 doi:10.26800/lv-144-9-10-3 (domaća recenzija, članak, znanstveni)
-
17.Estimated Plasma Volume Status in Patients With Primary Myelofibrosis and Associated Thrombotic and Mortality Risks // Clinical Lymphoma, Myeloma & Leukemia 22 Suppl. 2: Society of Hematologic Oncology Tenth Annual Meeting
Houston (TX), Sjedinjene Američke Države, 2022. str. S341-S342 doi:10.1016/s2152-2650(22)01467-7 (predavanje, međunarodna recenzija, sažetak, znanstveni) -
18.Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis // Leukemia research, 119 (2022), 106905, 4 doi:10.1016/j.leukres.2022.106905 (međunarodna recenzija, kratko priopcenje, znanstveni)
-
19.Comparison of IMPROVE, modified IMPROVE, IMPROVEDD, Padua and CHA2DS2-VASC risk scores for venous and arterial thrombotic events prediction in hospitalized COVID-19 patients // Thrombosis research, 214 (2022), 37-39 doi:10.1016/j.thromres.2022.04.009 (međunarodna recenzija, članak, znanstveni)
-
20.Gradual increase in red cell distribution width is similarly prognostic for in-hospital mortality in both anemic and non-anemic COVID-19 patients // Journal of medical virology, 94 (2022), 8; 3509-3511 doi:10.1002/jmv.27785 (međunarodna recenzija, pismo, znanstveni)
-
21.Scurvy // Acta dermatovenerologica Croatica, 30 (2022), 1; 59-60 (međunarodna recenzija, pismo, znanstveni)
-
22.Serum osmolarity in polycythemia vera and its clinical associations // International journal of laboratory hematology, Online ahead of print. (2022), 1-4 doi:10.1111/ijlh.13844 (međunarodna recenzija, pismo, znanstveni)
-
23.Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate // Annals of hematology, 101 (2022), 8; 1885-1886 doi:10.1007/s00277-022-04839-2 (međunarodna recenzija, prikaz, znanstveni)
-
24.Persistent fever, bloody diarrhea, and skin necrosis in a young female // European journal of internal medicine, 101 (2022), 108-109 doi:10.1016/j.ejim.2022.05.008 (međunarodna recenzija, prikaz, znanstveni)
-
25.High platelet-to-lymphocyte ratio may differentiate polycythemia vera from secondary polycythemia // Wiener klinische Wochenschrift, 134 (2022), 11-12; 483-486 doi:10.1007/s00508-022-02027-w (međunarodna recenzija, članak, znanstveni)
